Related Experiment Video
Updated: Apr 7, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
Elisa Zanardi1, Elena Verzoni1, Paolo Grassi1
1Department of Medical Oncology, Istituto Nazionale dei Tumori, Milan, Italy.
Abstract:
Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as the first-line treatment indicated in mRCC patients classified as poor risk. The benefits of temsirolimus are not limited to an increased survival but are also related to a better quality of life, which is certainly one of the most important aspects in the clinical management of these frail patients. Temsirolimus is a well-tolerated treatment, and the most frequent adverse events are manageable with supportive care. To this end, the identification of predictive factors of response to temsirolimus could help us to better select patients and obtain a more tailored clinical management of mRCC.
Insights
Temsirolimus is a well-tolerated first-line treatment for metastatic renal cell carcinoma (mRCC) in poor-risk patients. It improves survival and quality of life, with manageable side effects.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) with poor prognosis is associated with high mammalian target of rapamycin (mTOR) kinase activity.
- mTOR pathway is a key target for mRCC treatment.
Purpose of the Study:
- To evaluate temsirolimus as a first-line treatment for poor-risk mRCC patients.
- To assess the impact of temsirolimus on survival and quality of life.
- To explore predictive factors for treatment response.
Main Methods:
- Clinical trial data analysis.
- Patient-reported outcome measures.
- Biomarker analysis for predictive factors.
Main Results:
- Temsirolimus demonstrated efficacy in improving survival in poor-risk mRCC patients.
- Patients treated with temsirolimus reported better quality of life.
- Temsirolimus was generally well-tolerated with manageable adverse events.
Conclusions:
- Temsirolimus is a recommended first-line therapy for poor-risk mRCC patients.
- The drug offers survival and quality-of-life benefits.
- Identifying predictive factors can optimize patient selection and treatment strategies.
More Related Videos
11:27Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers